Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
- Conditions
- Healthy Subjects
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT07015437
- Locations
- 🇺🇸
Hoxworth Blood Center, Cincinnati, Ohio, United States
🇺🇸American Red Cross Research Laboratory, Norfolk, Virginia, United States
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated with the INTERCEPT Blood System for Platelets with LED Illuminator.
- Conditions
- Healthy Subjects
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06697223
- Locations
- 🇺🇸
American Red Cross Research Laboratory, Norfolk, Virginia, United States
🇺🇸Bloodworks Northwest Research Institute, Seattle, Washington, United States
In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
- Conditions
- Healthy
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 37
- Registration Number
- NCT04022889
- Locations
- 🇺🇸
Hoxworth Blood Center, Cincinnati, Ohio, United States
🇺🇸Bloodworks Northwest Research Institute, Seattle, Washington, United States
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
- Conditions
- Anemia
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 321
- Registration Number
- NCT03459287
- Locations
- 🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
- Conditions
- Anemia
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 800
- Registration Number
- NCT03037164
- Locations
- 🇺🇸
Phoenix Children's Hospital (PCH), Phoenix, Arizona, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Cerus Corporation Reports Positive Phase 3 Results for INTERCEPT Blood System at ISBT Congress
Cerus Corporation will present positive Phase 3 ReCePI study results for its INTERCEPT Blood System red blood cell treatment at the 35th ISBT Congress in Milan.
Cerus Secures CE Mark for Next-Gen INTERCEPT Blood Pathogen Inactivation System
Cerus Corporation has received CE mark approval for its INT200, a next-generation LED-based illumination device for the INTERCEPT Blood System, enabling commercialization throughout the European Union.
Cerus Highlights INTERCEPT Blood System Advancements at AABB 2024
Cerus Corporation presented data at the AABB Annual Meeting showcasing the benefits of INTERCEPT-treated blood products.
Pathogen-Reduced Cryoprecipitate Trial Aims to Improve Transfusion Outcomes in Cardiac Surgery
A prospective, cluster-randomized trial is underway to compare pathogen-reduced cryoprecipitate (IFC) with conventional cryoprecipitated AHF in cardiac surgery patients.